A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
Therapy with two or more separate preparations given for a combined effect.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
Proteins prepared by recombinant DNA technology.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Ribonucleic acid that makes up the genetic material of viruses.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205.
A severe, often fatal disease in humans caused by the Crimean-Congo hemorrhagic fever virus (HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO).
A purine nucleoside that has guanine linked by its N9 nitrogen to the C1 carbon of ribose. It is a component of ribonucleic acid and its nucleotides play important roles in metabolism. (From Dorland, 28th ed)
A subtype of equilibrative nucleoside transporter proteins that is sensitive to inhibition by 4-nitrobenzylthioinosine.
Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
The return of a sign, symptom, or disease after a remission.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
A species of NAIROVIRUS of the family BUNYAVIRIDAE. It is primarily transmitted by ticks and causes a severe, often fatal disease in humans.
Infections with viruses of the genus RESPIROVIRUS, family PARAMYXOVIRIDAE. Host cell infection occurs by adsorption, via HEMAGGLUTININ, to the cell surface.
Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli.
Inoculation of a series of animals or in vitro tissue with an infectious bacterium or virus, as in VIRULENCE studies and the development of vaccines.
Diseases caused by American hemorrhagic fever viruses (ARENAVIRUSES, NEW WORLD).
The only genus in the family ARENAVIRIDAE. It contains two groups ARENAVIRUSES, OLD WORLD and ARENAVIRUSES, NEW WORLD, which are distinguished by antigenic relationships and geographic distribution.
Simultaneous infection of a host organism by two or more pathogens. In virology, coinfection commonly refers to simultaneous infection of a single cell by two or more different viruses.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.

Inhibition of vaccinia virus growth by the nucleoside analogue 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ribavirin). (1/1584)

Virazole or Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) inhibits the growth of vaccinia virus at a concentration ode to a certain extent in the presence of Virazole, the DNA fails to acquire resistance to deoxyribonuclease and virus particles are not formed. Reversibility of the antiviral effect occurs when the drug is washed out from the infected cultures or when guanosine at an equimolar concentration is added.  (+info)

SVMPA, a mutant of sindbis virus resistant to mycophenolic acid and ribavirin, shows an increased sensitivity to chick interferon. (2/1584)

SVMPA is a mutant of Sindbis virus, selected for its ability to replicate in mycophenolic acid (MPA)-treated mosquito cells. SVMPA has another phenotype: although able to replicate normally in primary cultures of chick embryo fibroblasts (CEF), its replication is restricted in secondary cultures prepared from aged primary CEF cultures. The mutations responsible for these phenotypes mapped to the region of the viral genome that codes for nsP1. We report here that SVMPA has yet another phenotype. Relative to our standard Sindbis virus (SVSTD) from which it was derived, SVMPA shows an increased sensitivity to chick interferon, both crude interferon prepared from virus-infected cells and recombinant interferon. Characterization of viral mutants obtained after site-directed mutagenesis indicated that the same mutations responsible for the host restriction of SVMPA in secondary cultures of CEF were also responsible for its increased sensitivity to chick interferon.  (+info)

Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. (3/1584)

Fulminant hepatic failure due to adenovirus infection is a rare complication following stem cell transplantation. We report this complication in an unrelated bone marrow transplant recipient 30 weeks post-transplant. Treatment with intravenous ribavirin was started within 36 h of admission, but he succumbed to unusually fulminant hepatic failure. Adenovirus type 2 was isolated from stool surveillance samples and from post-mortem liver samples. Adenovirus DNA was detected by PCR in blood and sputum samples at admission and was identified in post-mortem liver tissue by electron microscopy. Implications of the failure of ribavirin therapy are discussed.  (+info)

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. (4/1584)

Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. However, a large number of patients do not respond even to combination therapy. Nonresponsiveness to IFN is characterized by evolution of the hepatitis C virus (HCV) quasispecies. Little is known about the changes occurring within the HCV genomes when nonresponder patients are retreated with IFN or with IFN plus ribavirin. In the present study we have examined the genetic divergence of HCV quasispecies during unsuccessful retreatment with IFN or IFN plus ribavirin. Fifteen nonresponder patients with HCV-1 (4 patients with HCV-1a and 11 patients with HCV-1b) infection were studied while being retreated for 2 months (phase 1) with IFN-alpha (6 MU given three times a week), followed by IFN plus ribavirin or IFN alone for an additional 6 months (phase 2). HCV quasispecies diversification in the E2 hypervariable region-1 (HVR1) and in the putative NS5A IFN sensitivity determining region (ISDR) were analyzed for phase 1 and phase 2 by using the heteroduplex tracking assay and clonal frequency analysis techniques. A major finding of this study was the relatively rapid evolution of the HCV quasispecies observed in both treatment groups during the early phase 1 compared to the late phase 2 of treatment. The rate of quasispecies diversification in HVR1 was significantly higher during phase 1 versus phase 2 both in patients who received IFN plus ribavirin (P = 0.017) and in patients who received IFN alone (P = 0. 05). A trend toward higher rates of quasispecies evolution in the ISDR was also observed during phase 1 in both groups, although the results did not reach statistical significance. However, the NS5A quasispecies appeared to be rather homogeneous and stable in most nonresponder patients, suggesting the presence of a single well-fit major variant, resistant to antiviral treatment, in agreement with published data which have identified an IFN sensitivity determinant region within the NS5A. During the entire 8 months of retreatment, there was no difference in the rate of fixation of mutation between patients who received combination therapy and patients who were treated with IFN alone, suggesting that ribavirin had no major effects on the evolution of the HCV quasispecies after the initial 2 months of IFN therapy.  (+info)

Inhibition of Borna disease virus replication by ribavirin. (5/1584)

The guanosine analogue ribavirin was tested for antiviral activity in two neural cell lines, human oligodendrocytes and rat glia, against Borna disease virus (BDV) strains V and He/80. Ribavirin treatment resulted in lower levels of virus and viral transcripts within 12 h. Addition of guanosine but not adenosine resulted in a profound reduction of the ribavirin effect. Ribavirin appears to be an effective antiviral agent for treatment of BDV infection in vitro. A likely mechanism for its activity is reduction of the intracellular GTP pool, resulting in inhibition of transcription and capping of BDV mRNAs.  (+info)

Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. (6/1584)

Hepatitis C is emerging as a serious worldwide problem. In the United States the current mortality figures may triple in the next ten years, rivaling HIV. The disease has a latency of 10-30 years and symptoms or signs may not appear until cirrhosis is evident. Adequate diagnosis, including liver biopsy, is essential in assessing the current stage of the viral infection and the need for treatment. Hepatitis C may manifest as hepatic fibrosis, cirrhosis, hepatocellular carcinoma, lichen planus, glomerulonephritis, mixed cryoglobulinemia, or porphyria. The hepatic damage is due both to the cytopathic effect of the virus and the inflammatory changes secondary to immune activation. The use of the botanical components glycyrrhizin, catechin, silymarin and phytosterols, and the antioxidants N-acetylcysteine and vitamin E are reviewed for their efficacy in treating chronic hepatitis and affecting liver damage.  (+info)

Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. (7/1584)

BACKGROUND: Hepatitis C virus (HCV) infection has been associated with mixed cryoglobulinaemia. AIM: To investigate the efficacy of anti-viral therapy on the eradication of HCV and its clinical manifestations in patients with HCV-associated symptomatic mixed cryoglobulinaemia. PATIENTS AND METHODS: 18 out of 32 patients with symptomatic mixed cryoglobulinaemia (MC group) received a 12-month course of interferon (3 MU three times a week, subcutaneously). Nonresponders or relapsers to this therapy were treated with interferon plus ribavirin (1200 mg/day, orally) for 12-months. 226 patients with HCV infection and without cryoglobulins were studied in comparison (Hepatitis C group). Serial quantification of serum HCV-RNA and cryoglobulins were performed. RESULTS: In the MC group, 10 out of 18 patients (55%) receiving interferon showed an end of treatment response, but at the end of follow-up, only five (28%) patients had a sustained response. In the hepatitis C group, 91 patients (47%) showed an end of treatment response but only 42 (20%) a sustained response. In the MC group alanine transaminase, cryocrit and rheumatoid factor decreased significantly in responders, with an improvement or disappearance of the MC-associated clinical manifestations. Alanine transaminase, cryocrit and rheumatoid factor increased in the relapsers and the clinical manifestations reappeared. Nonresponders and relapsers to interferon in the MC group were retreated with interferon plus ribavirin. Five out of eight nonresponders showed a end of treatment response but it was sustained in three of them. In the relapsers, treatment with combined therapy achieved a sustained response in four out of the five patients (80%). CONCLUSIONS: Interferon as monotherapy or combined with ribavirin is a safe and effective treatment in patients with HCV-associated MC. The presence of cryoglobulins does not affect the response to anti-viral treatment in patients with HCV infection. The eradication of HCV is associated with an improvement or disappearance of MC-associated clinical manifestations.  (+info)

Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. (8/1584)

Respiratory syncytial virus (RSV) has been reported as a cause of death among autologous peripheral blood stem cell (ASCT) and marrow recipients and recommendations for therapy with aerosolized ribavirin plus intravenous immunoglobulin (IVIG) made. This therapy is expensive, may be toxic, and causes a significant disruption of patient care. The purpose of this study was to evaluate the morbidity and mortality of RSV infections in patients with multiple myeloma undergoing ASCT without ribavirin therapy. During the months of February-April 1997, 10 consecutive patients (median age 57 years, seven males) with advanced and heavily pretreated myeloma underwent ASCT while having active RSV upper respiratory tract infection. After melphalan (200 mg/m2), all patients became neutropenic (<1000 cells/mm3) for a median of 7 days. Ribavirin was not given to any patient. No patient developed lower respiratory tract infection, required transfer to intensive care or died at a median follow-up of 8 months. One patient developed tracheobronchitis requiring oxygenation by nasal cannula. No delay in the treatment of the underlying myeloma was incurred. RSV infection may not necessarily be a contraindication for ASCT or an indication for therapy with aerosolized ribavirin. Additional studies are needed to confirm our preliminary findings.  (+info)

Ribavirin is an antiviral medication used in the treatment of certain viral infections, including hepatitis C and respiratory syncytial virus (RSV) infection. It works by interfering with viral replication, preventing the virus from multiplying within infected cells. Ribavirin is often used in combination with other antiviral drugs for more effective treatment.

It's important to note that ribavirin can have serious side effects and should only be used under the supervision of a healthcare professional. Additionally, it is not effective against all types of viral infections and its use should be based on a confirmed diagnosis and appropriate medical evaluation.

Antiviral agents are a class of medications that are designed to treat infections caused by viruses. Unlike antibiotics, which target bacteria, antiviral agents interfere with the replication and infection mechanisms of viruses, either by inhibiting their ability to replicate or by modulating the host's immune response to the virus.

Antiviral agents are used to treat a variety of viral infections, including influenza, herpes simplex virus (HSV) infections, human immunodeficiency virus (HIV) infection, hepatitis B and C, and respiratory syncytial virus (RSV) infections.

These medications can be administered orally, intravenously, or topically, depending on the type of viral infection being treated. Some antiviral agents are also used for prophylaxis, or prevention, of certain viral infections.

It is important to note that antiviral agents are not effective against all types of viruses and may have significant side effects. Therefore, it is essential to consult with a healthcare professional before starting any antiviral therapy.

Interferon-alpha (IFN-α) is a type I interferon, which is a group of signaling proteins made and released by host cells in response to the presence of viruses, parasites, and tumor cells. It plays a crucial role in the immune response against viral infections. IFN-α has antiviral, immunomodulatory, and anti-proliferative effects.

IFN-α is produced naturally by various cell types, including leukocytes (white blood cells), fibroblasts, and epithelial cells, in response to viral or bacterial stimulation. It binds to specific receptors on the surface of nearby cells, triggering a signaling cascade that leads to the activation of genes involved in the antiviral response. This results in the production of proteins that inhibit viral replication and promote the presentation of viral antigens to the immune system, enhancing its ability to recognize and eliminate infected cells.

In addition to its role in the immune response, IFN-α has been used as a therapeutic agent for various medical conditions, including certain types of cancer, chronic hepatitis B and C, and multiple sclerosis. However, its use is often limited by side effects such as flu-like symptoms, depression, and neuropsychiatric disorders.

Polyethylene glycols (PEGs) are a family of synthetic, water-soluble polymers with a wide range of molecular weights. They are commonly used in the medical field as excipients in pharmaceutical formulations due to their ability to improve drug solubility, stability, and bioavailability. PEGs can also be used as laxatives to treat constipation or as bowel cleansing agents prior to colonoscopy examinations. Additionally, some PEG-conjugated drugs have been developed for use in targeted cancer therapies.

In a medical context, PEGs are often referred to by their average molecular weight, such as PEG 300, PEG 400, PEG 1500, and so on. Higher molecular weight PEGs tend to be more viscous and have longer-lasting effects in the body.

It's worth noting that while PEGs are generally considered safe for use in medical applications, some people may experience allergic reactions or hypersensitivity to these compounds. Prolonged exposure to high molecular weight PEGs has also been linked to potential adverse effects, such as decreased fertility and developmental toxicity in animal studies. However, more research is needed to fully understand the long-term safety of PEGs in humans.

Chronic Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that lasts for more than six months. This long-term infection can lead to scarring of the liver (cirrhosis), which can cause serious health problems, such as liver failure or liver cancer, in some individuals. The infection is usually asymptomatic until complications arise, but it can be detected through blood tests that identify antibodies to the virus or viral RNA. Chronic hepatitis C is typically managed with antiviral therapy, which can help clear the virus from the body and reduce the risk of liver damage.

Ribonucleosides are organic compounds that consist of a nucleoside bound to a ribose sugar. Nucleosides are formed when a nitrogenous base (such as adenine, guanine, uracil, cytosine, or thymine) is attached to a sugar molecule (either ribose or deoxyribose) via a beta-glycosidic bond. In the case of ribonucleosides, the sugar component is D-ribose. Ribonucleosides play important roles in various biological processes, particularly in the storage, transfer, and expression of genetic information within cells. When ribonucleosides are phosphorylated, they become the building blocks of RNA (ribonucleic acid), a crucial biomolecule involved in protein synthesis and other cellular functions. Examples of ribonucleosides include adenosine, guanosine, uridine, cytidine, and inosine.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Hepacivirus is a genus of viruses in the family Flaviviridae. The most well-known member of this genus is Hepatitis C virus (HCV), which is a major cause of liver disease worldwide. HCV infection can lead to chronic hepatitis, cirrhosis, and liver cancer.

Hepaciviruses are enveloped viruses with a single-stranded, positive-sense RNA genome. They have a small icosahedral capsid and infect a variety of hosts, including humans, non-human primates, horses, and birds. The virus enters the host cell by binding to specific receptors on the cell surface and is then internalized through endocytosis.

HCV has a high degree of genetic diversity and is classified into seven major genotypes and numerous subtypes based on differences in its RNA sequence. This genetic variability can affect the virus's ability to evade the host immune response, making treatment more challenging.

In addition to HCV, other hepaciviruses have been identified in various animal species, including equine hepacivirus (EHCV), rodent hepacivirus (RHV), and bat hepacivirus (BtHepCV). These viruses are being studied to better understand the biology of hepaciviruses and their potential impact on human health.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It's primarily spread through contact with contaminated blood, often through sharing needles or other equipment to inject drugs. For some people, hepatitis C is a short-term illness but for most — about 75-85% — it becomes a long-term, chronic infection that can lead to serious health problems like liver damage, liver failure, and even liver cancer. The virus can infect and inflame the liver, causing symptoms like jaundice (yellowing of the skin and eyes), abdominal pain, fatigue, and dark urine. Many people with hepatitis C don't have any symptoms, so they might not know they have the infection until they experience complications. There are effective treatments available for hepatitis C, including antiviral medications that can cure the infection in most people. Regular testing is important to diagnose and treat hepatitis C early, before it causes serious health problems.

A viral RNA (ribonucleic acid) is the genetic material found in certain types of viruses, as opposed to viruses that contain DNA (deoxyribonucleic acid). These viruses are known as RNA viruses. The RNA can be single-stranded or double-stranded and can exist as several different forms, such as positive-sense, negative-sense, or ambisense RNA. Upon infecting a host cell, the viral RNA uses the host's cellular machinery to translate the genetic information into proteins, leading to the production of new virus particles and the continuation of the viral life cycle. Examples of human diseases caused by RNA viruses include influenza, COVID-19 (SARS-CoV-2), hepatitis C, and polio.

Viral load refers to the amount or quantity of virus (like HIV, Hepatitis C, SARS-CoV-2) present in an individual's blood or bodily fluids. It is often expressed as the number of virus copies per milliliter of blood or fluid. Monitoring viral load is important in managing and treating certain viral infections, as a higher viral load may indicate increased infectivity, disease progression, or response to treatment.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Amantadine is an antiviral medication that is primarily used to prevent and treat certain types of influenza (flu). It works by stopping the virus from multiplying in your body. In addition to its antiviral properties, amantadine also has central nervous system (CNS) stimulant and dopaminergic effects, which make it useful in the treatment of Parkinson's disease and various movement disorders.

The medical definition of Amantadine is:

A synthetic symmetrical tricyclic amine used as an antiviral agent to treat and prevent influenza A infection and as an anti-parkinsonian drug to control extrapyramidal symptoms caused by neuroleptic agents. The antiviral effect may be due to interference with viral uncoating or replication. The anti-parkinsonian effect may be due to a combination of dopamine agonist and NMDA receptor antagonist properties. (Stedman's Medical Dictionary, 28th edition)

Please note that the use of Amantadine for various medical conditions should always be under the supervision of a healthcare professional, as they will consider potential benefits and risks and provide appropriate guidance.

Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, or tumor cells. They belong to the larger family of cytokines and are crucial for the innate immune system's defense against infections. Interferons exist in multiple forms, classified into three types: type I (alpha and beta), type II (gamma), and type III (lambda). These proteins play a significant role in modulating the immune response, inhibiting viral replication, regulating cell growth, and promoting apoptosis of infected cells. Interferons are used as therapeutic agents for various medical conditions, including certain viral infections, cancers, and autoimmune diseases.

Genotype, in genetics, refers to the complete heritable genetic makeup of an individual organism, including all of its genes. It is the set of instructions contained in an organism's DNA for the development and function of that organism. The genotype is the basis for an individual's inherited traits, and it can be contrasted with an individual's phenotype, which refers to the observable physical or biochemical characteristics of an organism that result from the expression of its genes in combination with environmental influences.

It is important to note that an individual's genotype is not necessarily identical to their genetic sequence. Some genes have multiple forms called alleles, and an individual may inherit different alleles for a given gene from each parent. The combination of alleles that an individual inherits for a particular gene is known as their genotype for that gene.

Understanding an individual's genotype can provide important information about their susceptibility to certain diseases, their response to drugs and other treatments, and their risk of passing on inherited genetic disorders to their offspring.

Inosine Monophosphate Dehydrogenase (IMDH or IMPDH) is an enzyme that is involved in the de novo biosynthesis of guanine nucleotides. It catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), which is the rate-limiting step in the synthesis of guanosine triphosphate (GTP).

There are two isoforms of IMPDH, type I and type II, which are encoded by separate genes. Type I IMPDH is expressed in most tissues, while type II IMPDH is primarily expressed in lymphocytes and other cells involved in the immune response. Inhibitors of IMPDH have been developed as immunosuppressive drugs to prevent rejection of transplanted organs. Defects in the gene encoding IMPDH type II have been associated with retinal degeneration and hearing loss.

Crimean hemorrhagic fever (CHF) is a tick-borne disease caused by the virus named Crimean-Congo hemorrhagic fever virus (CCHFV). It is a severe and often fatal illness. The disease is characterized by sudden onset of high fever, muscle pain, severe headache, soreness in the eyes, fatigue, and dizziness. After two to four days, there may be evidence of hemorrhage (bleeding) from the mouth, gums, nose, or other sites. The virus is primarily transmitted to people from ticks that feed on domestic animals such as cattle, sheep, and goats. It can also be transmitted through contact with infected animal blood or tissues during and after slaughtering. Human-to-human transmission can occur resulting from close contact with the blood, secretions, organs or other bodily fluids of infected persons. Healthcare workers are at risk if they are not wearing appropriate personal protective equipment. There is no specific treatment for CHF yet, but early supportive care and symptomatic treatment improve survival rates.

Guanosine is a nucleoside that consists of a guanine base linked to a ribose sugar molecule through a beta-N9-glycosidic bond. It plays a crucial role in various biological processes, such as serving as a building block for DNA and RNA during replication and transcription. Guanosine triphosphate (GTP) and guanosine diphosphate (GDP) are important energy carriers and signaling molecules involved in intracellular regulation. Additionally, guanosine has been studied for its potential role as a neuroprotective agent and possible contribution to cell-to-cell communication.

Equilibrative Nucleoside Transporter 1 (ENT1), also known as SLC29A1, is a protein that functions as a membrane transport protein. It is responsible for the facilitated diffusion of nucleosides and some related drugs across the cell membrane. The term "equilibrative" refers to the fact that this transporter moves substrates down their concentration gradient, meaning it facilitates the movement of molecules from an area of high concentration to an area of low concentration. ENT1 is widely expressed in various tissues, including the liver, kidney, intestine, and brain, playing a crucial role in nucleoside homeostasis and the cellular uptake of nucleoside-analog drugs used in cancer chemotherapy.

Aerosols are defined in the medical field as suspensions of fine solid or liquid particles in a gas. In the context of public health and medicine, aerosols often refer to particles that can remain suspended in air for long periods of time and can be inhaled. They can contain various substances, such as viruses, bacteria, fungi, or chemicals, and can play a role in the transmission of respiratory infections or other health effects.

For example, when an infected person coughs or sneezes, they may produce respiratory droplets that can contain viruses like influenza or SARS-CoV-2 (the virus that causes COVID-19). Some of these droplets can evaporate quickly and leave behind smaller particles called aerosols, which can remain suspended in the air for hours and potentially be inhaled by others. This is one way that respiratory viruses can spread between people in close proximity to each other.

Aerosols can also be generated through medical procedures such as bronchoscopy, suctioning, or nebulizer treatments, which can produce aerosols containing bacteria, viruses, or other particles that may pose an infection risk to healthcare workers or other patients. Therefore, appropriate personal protective equipment (PPE) and airborne precautions are often necessary to reduce the risk of transmission in these settings.

Alanine transaminase (ALT) is a type of enzyme found primarily in the cells of the liver and, to a lesser extent, in the cells of other tissues such as the heart, muscles, and kidneys. Its primary function is to catalyze the reversible transfer of an amino group from alanine to another alpha-keto acid, usually pyruvate, to form pyruvate and another amino acid, usually glutamate. This process is known as the transamination reaction.

When liver cells are damaged or destroyed due to various reasons such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, or drug-induced liver injury, ALT is released into the bloodstream. Therefore, measuring the level of ALT in the blood is a useful diagnostic tool for evaluating liver function and detecting liver damage. Normal ALT levels vary depending on the laboratory, but typically range from 7 to 56 units per liter (U/L) for men and 6 to 45 U/L for women. Elevated ALT levels may indicate liver injury or disease, although other factors such as muscle damage or heart disease can also cause elevations in ALT.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Liver cirrhosis is a chronic, progressive disease characterized by the replacement of normal liver tissue with scarred (fibrotic) tissue, leading to loss of function. The scarring is caused by long-term damage from various sources such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, and other causes. As the disease advances, it can lead to complications like portal hypertension, fluid accumulation in the abdomen (ascites), impaired brain function (hepatic encephalopathy), and increased risk of liver cancer. It is generally irreversible, but early detection and treatment of underlying causes may help slow down its progression.

Virus replication is the process by which a virus produces copies or reproduces itself inside a host cell. This involves several steps:

1. Attachment: The virus attaches to a specific receptor on the surface of the host cell.
2. Penetration: The viral genetic material enters the host cell, either by invagination of the cell membrane or endocytosis.
3. Uncoating: The viral genetic material is released from its protective coat (capsid) inside the host cell.
4. Replication: The viral genetic material uses the host cell's machinery to produce new viral components, such as proteins and nucleic acids.
5. Assembly: The newly synthesized viral components are assembled into new virus particles.
6. Release: The newly formed viruses are released from the host cell, often through lysis (breaking) of the cell membrane or by budding off the cell membrane.

The specific mechanisms and details of virus replication can vary depending on the type of virus. Some viruses, such as DNA viruses, use the host cell's DNA polymerase to replicate their genetic material, while others, such as RNA viruses, use their own RNA-dependent RNA polymerase or reverse transcriptase enzymes. Understanding the process of virus replication is important for developing antiviral therapies and vaccines.

Crimean-Congo Hemorrhagic Fever (CCHF) is a viral disease transmitted to humans through tick bites or contact with infected animal blood or tissues during and after slaughter. The virus belongs to the Nairovirus genus in the Bunyaviridae family. The disease was first identified in Crimea in 1944 and later in the Congo in 1956, hence the name Crimean-Congo Hemorrhagic Fever.

The CCHF virus causes severe illness with a case fatality rate of up to 40% in hospitalized patients. The symptoms include sudden onset of fever, muscle pain, headache, dizziness, neck pain and stiffness, back pain, sore eyes, and sensitivity to light. After a few days, patients may develop nausea, vomiting, diarrhea, abdominal pain, and bleeding from the mouth, nose, gums, and private parts.

There is no specific treatment or vaccine available for CCHF, but early supportive care with oral or intravenous fluids, analgesics, and antipyretics can significantly reduce mortality. Ribavirin has been used in the treatment of severe cases, but its efficacy is not fully proven. Preventive measures include avoiding tick bites, using protective clothing and gloves while handling animals or their tissues, and practicing good hygiene and food safety.

Respiroviruses are a genus of viruses in the family *Paramyxoviridae* that includes several important human pathogens, such as parainfluenza virus (PIV) types 1, 2, and 3, and human respiratory syncytial virus (HRSV). These viruses are primarily transmitted through respiratory droplets and direct contact with infected individuals.

Respirovirus infections mainly affect the respiratory tract and can cause a range of symptoms, from mild upper respiratory tract illness to severe lower respiratory tract infections. The severity of the disease depends on various factors, including the age and overall health status of the infected individual.

Parainfluenza viruses are a common cause of acute respiratory infections in children, particularly in those under five years old. They can lead to croup, bronchitis, pneumonia, and other respiratory tract complications. In adults, PIV infections are usually less severe but can still cause upper respiratory symptoms, such as the common cold.

Human respiratory syncytial virus is another important respirovirus that primarily affects young children, causing bronchiolitis and pneumonia. Reinfection with HRSV can occur throughout life, although subsequent infections are typically less severe than the initial infection. In older adults and individuals with compromised immune systems, HRSV infections can lead to serious complications, including pneumonia and exacerbation of chronic lung diseases.

Prevention strategies for respirovirus infections include good personal hygiene practices, such as frequent handwashing and covering the mouth and nose when coughing or sneezing. Vaccines are not available for most respiroviruses; however, research is ongoing to develop effective vaccines against these viruses, particularly HRSV.

Interleukins (ILs) are a group of naturally occurring proteins that are important in the immune system. They are produced by various cells, including immune cells like lymphocytes and macrophages, and they help regulate the immune response by facilitating communication between different types of cells. Interleukins can have both pro-inflammatory and anti-inflammatory effects, depending on the specific interleukin and the context in which it is produced. They play a role in various biological processes, including the development of immune responses, inflammation, and hematopoiesis (the formation of blood cells).

There are many different interleukins that have been identified, and they are numbered according to the order in which they were discovered. For example, IL-1, IL-2, IL-3, etc. Each interleukin has a specific set of functions and targets certain types of cells. Dysregulation of interleukins has been implicated in various diseases, including autoimmune disorders, infections, and cancer.

"Serial passage" is a term commonly used in the field of virology and microbiology. It refers to the process of repeatedly transmitting or passing a virus or other microorganism from one cultured cell line or laboratory animal to another, usually with the aim of adapting the microorganism to grow in that specific host system or to increase its virulence or pathogenicity. This technique is often used in research to study the evolution and adaptation of viruses and other microorganisms.

Hemorrhagic fever, American is a group of viral diseases that are transmitted to humans by infected ticks, mosquitoes or rodents. The most common types of American hemorrhagic fevers include:

1. Hantavirus Pulmonary Syndrome (HPS): It is caused by Sin Nombre virus and is transmitted to humans through inhalation of aerosolized urine, droppings or saliva of infected rodents.
2. Colorado Tick Fever (CTF): It is caused by a Coltivirus and is transmitted to humans through the bite of an infected tick.
3. Venezuelan Equine Encephalitis (VEE): It is caused by an Alphavirus and is transmitted to humans through the bite of an infected mosquito.
4. Eastern Equine Encephalitis (EEE) and Western Equine Encephalitis (WEE): They are also caused by Alphaviruses and are transmitted to humans through the bite of an infected mosquito.

These diseases are called hemorrhagic fevers because they are characterized by bleeding disorders, high fever, muscle and joint pain, headache, and fatigue. In severe cases, they can lead to shock, organ failure, and death. There are no specific treatments for these diseases, but early detection and supportive care can improve outcomes. Prevention measures include avoiding contact with rodents, using insect repellent, and wearing protective clothing in areas where the diseases are common.

Arenavirus is a type of virus that belongs to the family Arenaviridae. These viruses are enveloped and have a single-stranded, bi-segmented RNA genome. They are named after the Latin word "arena" which means "sand" because their virions contain ribosomes which resemble sand granules when viewed under an electron microscope.

Arenaviruses are primarily associated with rodents and can cause chronic infection in their natural hosts. Some arenaviruses can also infect humans and other animals, causing severe hemorrhagic fevers. Examples of human diseases caused by arenaviruses include Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.

These viruses are typically transmitted to humans through contact with infected rodents or their excreta, but some can also be spread from person to person through close contact with an infected individual's blood or other bodily fluids. There are currently no vaccines available for most arenaviruses, and treatment is primarily supportive, focusing on managing symptoms and complications.

Coinfection is a term used in medicine to describe a situation where a person is infected with more than one pathogen (infectious agent) at the same time. This can occur when a person is infected with two or more viruses, bacteria, parasites, or fungi. Coinfections can complicate the diagnosis and treatment of infectious diseases, as the symptoms of each infection can overlap and interact with each other.

Coinfections are common in certain populations, such as people who are immunocompromised, have chronic illnesses, or live in areas with high levels of infectious agents. For example, a person with HIV/AIDS may be more susceptible to coinfections with tuberculosis, hepatitis, or pneumocystis pneumonia. Similarly, a person who has recently undergone an organ transplant may be at risk for coinfections with cytomegalovirus, Epstein-Barr virus, or other opportunistic pathogens.

Coinfections can also occur in people who are otherwise healthy but are exposed to multiple infectious agents at once, such as through travel to areas with high levels of infectious diseases or through close contact with animals that carry infectious agents. For example, a person who travels to a tropical area may be at risk for coinfections with malaria and dengue fever, while a person who works on a farm may be at risk for coinfections with influenza and Q fever.

Effective treatment of coinfections requires accurate diagnosis and appropriate antimicrobial therapy for each pathogen involved. In some cases, treating one infection may help to resolve the other, but in other cases, both infections may need to be treated simultaneously to achieve a cure. Preventing coinfections is an important part of infectious disease control, and can be achieved through measures such as vaccination, use of personal protective equipment, and avoidance of high-risk behaviors.

Drug resistance, viral, refers to the ability of a virus to continue replicating in the presence of antiviral drugs that are designed to inhibit or stop its growth. This occurs when the virus mutates and changes its genetic makeup in such a way that the drug can no longer effectively bind to and inhibit the function of its target protein, allowing the virus to continue infecting host cells and causing disease.

Viral drug resistance can develop due to several factors, including:

1. Mutations in the viral genome that alter the structure or function of the drug's target protein.
2. Changes in the expression levels or location of the drug's target protein within the virus-infected cell.
3. Activation of alternative pathways that allow the virus to replicate despite the presence of the drug.
4. Increased efflux of the drug from the virus-infected cell, reducing its intracellular concentration and effectiveness.

Viral drug resistance is a significant concern in the treatment of viral infections such as HIV, hepatitis B and C, herpes simplex virus, and influenza. It can lead to reduced treatment efficacy, increased risk of treatment failure, and the need for more toxic or expensive drugs. Therefore, it is essential to monitor viral drug resistance during treatment and adjust therapy accordingly to ensure optimal outcomes.

... has also been used as a treatment for herpes simplex virus. One small study found that ribavirin treatment reduced ... The mechanism of action of ribavirin is not entirely clear. Ribavirin was patented in 1971 and approved for medical use in 1986 ... 1980). "Ribavirin: structure and antiviral activity relationships". Ribavirin: A Broad Spectrum Antiviral Agent. New York: ... "Ribavirin (Ibavyr)". Catie. 2022. Retrieved 22 August 2022. "PRODUCT INFORMATION REBETOL (RIBAVIRIN) CAPSULES" (PDF). TGA ...
"COPEGUS (RIBAVIRIN) TABLET, FILM COATED [GENENTECH, INC]". DailyMed. Genentech, Inc. February 2013. Retrieved 23 February 2014 ... List of adverse effects of ribavirin by frequency. Abdominal pain Anemia Anxiety Appetite loss Concentration impaired ... RIBAVIRIN) CAPSULES" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 29 April 2013. Retrieved 23 ...
"Ribavirin History". News-Medical.net. 12 April 2010. Retrieved 19 February 2016. "Aerosolization of Ribavirin through a Mask, ... In 1985, ribavirin was approved under the name Virazole by the Food and Drug Administration for the treatment of respiratory ... In 1991, ICN created the SPAG-2 (Small Particle Aerosol Generator) nebulizer to administer an aerosolized form of ribavirin ... "Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. ...
The antiviral medication ribavirin has been recommended, but evidence to support its use is weak. Descriptions of the disease ... Effective therapy with ribavirin". The New England Journal of Medicine. 314 (1): 20-26. doi:10.1056/NEJM198601023140104. ISSN ... Because of treatment with ribavirin, fatality rates have declined. There are about 300,000 to 500,000 cases which result in ... Eberhardt, KA; Mischlinger, J; Jordan, S; Groger, M; Günther, S; Ramharter, M (October 2019). "Ribavirin for the treatment of ...
Ribavirin was not given in these first two cases. Four years later, in 1994, a researcher was exposed to the virus in a level 3 ... Ribavirin is thought to be effective in treating the illness, similar to other arenaviruses. Compared to the patients who did ... He was successfully treated with ribavirin. A fifth case, also naturally acquired in upstate São Paulo, was reported in January ... not receive ribavirin, the patient who was treated with it had a shorter and less severe clinical course. Symptomatic control ...
When Viekira Pak was used without ribavirin, nausea, severe itching, and insomnia occurred in more than 5% of the subjects. ... The co-packaged dasabuvir and ombitasvir/paritaprevir/ritonavir is used in combination with ribavirin for the treatment of ... Some people taking dasabuvir are also treated with another antiviral medicine, ribavirin, in addition to ombitasvir/ ... Ribavirin may also additionally be used. These combinations result in a cure in more than 90% of people. It is taken by mouth. ...
... and Ribavirin. Gastroenterology 2009b; 136:856-862. (BLP articles lacking sources from July 2018, All BLP articles lacking ...
2010). "Ribavirin for Lassa fever postexposure prophylaxis". Emerg Infect Dis. 16 (12): 2009-11. doi:10.3201/eid1612.100994. ... Post-exposure prophylactic (preventive) ribavirin may be effective for some bunyavirus and arenavirus infections. VHF isolation ... Antiviral therapy with intravenous ribavirin may be useful in Bunyaviridae and Arenaviridae infections (specifically Lassa ...
Ribavirin has shown some efficacy in vitro and has been used by mouth during outbreaks,[citation needed] but there is uncertain ... Treatment is typically with supportive care, and the medication ribavirin may also help. CCHF cases are observed in a wide ... Alternatively, many scientists appear to believe that treatment of CCHF with ribavirin is more practical than prevention, but ... Cochrane Infectious Diseases Group) (June 2018). "Ribavirin for treating Crimean Congo haemorrhagic fever". The Cochrane ...
Other studies used ribavirin in combination showed similar promising results in head and neck cancer. Ribavirin impairs all of ... Subsequent ribavirin trials in AML in combination with antileukemic drugs again showed objective clinical responses including ... In the first clinical trials targeting eIF4E, old antiviral drug ribavirin was used as a m7G cap competitor which had ... In the first trial to ever target eIF4E, ribavirin monotherapy was demonstrated to inhibit eIF4E activity leading to objective ...
Use with ribavirin is not recommended during pregnancy. Pegylated interferon alfa-2a is in the alpha interferon family of ... For genotype 1 hepatitis C treated with pegylated interferon alfa-2a or pegylated interferon alfa-2b combined with ribavirin, ... For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be ...
Ribavirin, m102.4 monoclonal antibody, and favipiravir were being studied as treatments as of 2019. Ribavirin has been studied ... While tentative evidence supports the use of ribavirin, it has not yet been studied in people with the disease. Specific ... In vitro studies and animal studies have shown conflicting results in the efficacy of ribavirin against NiV and Hendra, with ... May 2006). "Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection". Antimicrobial ...
IFN-β 1b have been shown in an open label randomised controlled trial in combination with lopinavir/ ritonavir and ribavirin to ... Coronaviruses species possess an intrinsic resistance to ribavirin. Sofosbuvir/daclatasvir is a drug combination developed to ... These include favipiravir, remdesivir, ribavirin, triazavirin, and umifenovir. The combination of artesunate/pyronaridine was ...
430-434 Crotty S, Camerson SE, Andino R (2001). RNA virus error catastrophe: direct molecular test using ribavirin. Proceedings ...
Gish RG (January 2006). "Treating HCV with ribavirin analogues and ribavirin-like molecules". The Journal of Antimicrobial ... "Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. ...
February 2008). "In vitro efficacy of ribavirin against canine distemper virus". Antiviral Res. 77 (2): 108-113. doi:10.1016/j. ...
Gish RG (January 2006). "Treating HCV with ribavirin analogues and ribavirin-like molecules". The Journal of Antimicrobial ... It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ... It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include ... Taribavirin is as active against influenza as ribavirin in animal models, with slightly less toxicity, so it may also ...
Crotty S, Cameron CE, Andino R (2001). "RNA virus error catastrophe: Direct molecular test by using ribavirin". Proceedings of ... "The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen". Nature Medicine. 6 (12): 1375-1379. doi:10.1038 ...
These experiments revealed that ribavirin-TP, which is made of similar building blocks to RNA, is incorporated into the viral ... He went on to demonstrate that ribavirin works by creating extreme mutation within viruses that forces them into genetic melt ... To study the mechanism of action of ribavirin-based antivirals, Cameron developed an analytical assay that could monitor ... Cameron developed lethal mutagenesis; an alternative mechanism of action of ribavirin that renders genes unable to function. He ...
As his condition worsened, he was treated with intravenous ribavirin. Conteh initially survived the critical stage of Lassa ...
Ribavirin also has shown some promise in treating arenaviral diseases. The disease was first detected in the 1950s in the Junín ...
Studies have shown that treating RNA viruses such as poliovirus with ribavirin produce results consistent with the idea that ... Crotty S, Cameron CE, Andino R (June 2001). "RNA virus error catastrophe: direct molecular test by using ribavirin". ...
This is the case of favipiravir (T-705; 6-fluoro-3-hydroxy-2-pirazinecarboxamide) and ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4- ... For example, increased doses of the mutagen ribavirin reduces the infectivity of poliovirus. However, these models assume that ... Crotty S, Cameron CE, Andino R (June 2001). "RNA virus error catastrophe: direct molecular test by using ribavirin". ...
Pegylated interferon and ribavirin are useful in reducing viral load. Diffuse proliferative nephritis Colville D, Guymer R, ...
A combination of mycophenolate and ribavirin has been found to stop infection by and replication of dengue virus in vitro. It ... "Inhibition of dengue virus replication by mycophenolic acid and ribavirin". The Journal of General Virology. 87 (Pt 7): 1947-52 ...
ELECTRON: 100% Suppression of Viral Load through 4 Weeks' Post-treatment for Sofosbuvir + Ledipasvir (GS-5885) + Ribavirin for ... CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response Archived 2015-09-24 at the ... and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive ... without interferon and ribavirin. On 10 October 2014 the FDA approved the combination product ledipasvir/sofosbuvir called ...
Treatment of children has been with interferon and ribavirin. The response to treatment is similar to that in adults. It shows ... Both pegylated interferon and ribavirin are unsuitable for use in pregnancy and infancy: newer methods of treatment are ...
During pregnancy when used with ribavirin it may cause harm to the baby while when used with sofosbuvir its safety is unclear. ... If pregnant women are exposed to any medication regimen containing ribavirin, they are encouraged to report this through the ... Simeprevir is administered as one capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 or ... "Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks". hivandhepatitis.com. 27 December ...
Intravenous ribavirin is effective against La Crosse encephalitis virus in the laboratory, and several studies in patients with ... In a trial with 15 children being infected with La Crosse viral encephalitis were treated at certain phases with ribavirin (RBV ... McJunkin, JE (October 2011). "Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis". The ...
"Rebetol- ribavirin capsule Rebetol- ribavirin liquid". DailyMed. Retrieved 26 January 2022. Bhatia HK, Singh H, Grewal N, Natt ... However, when used in combination with ribavirin or peginterferon alfa/ribavirin, or others, the contraindications applicable ... However, ribavirin, a medication that is often given together with sofosbuvir to treat hepatitis C, is assigned a Pregnancy ... Pregnant women with hepatitis C who take ribavirin have shown some cases of birth defects and death in their fetus. It is ...
Ribavirin has also been used as a treatment for herpes simplex virus. One small study found that ribavirin treatment reduced ... The mechanism of action of ribavirin is not entirely clear. Ribavirin was patented in 1971 and approved for medical use in 1986 ... 1980). "Ribavirin: structure and antiviral activity relationships". Ribavirin: A Broad Spectrum Antiviral Agent. New York: ... "Ribavirin (Ibavyr)". Catie. 2022. Retrieved 22 August 2022. "PRODUCT INFORMATION REBETOL (RIBAVIRIN) CAPSULES" (PDF). TGA ...
Ribavirin: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Do not take ribavirin if you are pregnant or plan to become pregnant. You should not start taking ribavirin until a pregnancy ... Before taking ribavirin,. *tell your doctor and pharmacist if you are allergic to ribavirin, any other medications, or any of ... Call your doctor if you are bothered by side effects of ribavirin. Do not decrease your dose or stop taking ribavirin unless ...
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine analogue and a commonly used antiviral agent against ... Conversely, the 2 deoxyribose version of ribavirin does not exhibit antiviral activity, suggesting that ribavirin requires RNA ... A convenient and simple way to synthesize polymerizable ribavirin derivatives is via transesterification between ribavirin and ... Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine analogue and a commonly used antiviral agent against ...
Assay for Ribavirin for Inhalation Solution, USP in human materials is by a radioimmunoassay which detects ribavirin and at ... Ribavirin is a synthetic nucleoside with antiviral activity. Ribavirin for inhalation solution, USP is a sterile, lyophilized ... In vivo carcinogenicity studies with ribavirin are incomplete. However, results of a chronic feeding study with ribavirin in ... RIBAVIRIN powder, for solution. To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader ...
Compare ribavirin prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. ... Ribavirin prices. Inhalation Powder For Reconstitution. 6 g ribavirin inhalation powder for reconstitution ... Brand names for ribavirin include Virazole. The cost for ribavirin oral capsule 200 mg is around $71 for a supply of 42 ... Ribavirin Prices, Coupons and Patient Assistance Programs. Ribavirin is a member of the inhaled anti-infectives drug class and ...
... once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced ... significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or ... We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and ... once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced ...
PEG-IFN therapy with ribavirin. The addition of ribavirin to PEG-IFN heralded a new era in the treatment of chronic HCV. The ... 121] ; SVR12 was 97% for 12 weeks of treatment with ribavirin but 90% without ribavirin (PEARL-IV study) [124] ... ENABLE 1 utilized PEG-IFN alfa-2a plus ribavirin for antiviral treatment and ENABLE 2 utilized PEG-IFN alfa-2b plus ribavirin. ... Treatment included simeprevir 150 mg once daily plus PEG-IFN and ribavirin for 12 weeks, followed by PEG-IFN and ribavirin ...
My taking ribavirin was in relation to being treated for hepatitis C and my therapy was experimental and lasted 100 weeks. Many ... As I stated in my initial post I know nothing of ribavirin effects on herpes virus. I do know that it is a nucleotide mimic and ... HCV patients will take ribavirin for 24-48 weeks dependent on genotype. For herpes its anyones guess but the cautions on ... Whos tried Ribavirin? #19099 19 years ago 3,553 * I was jsut surfing by and had to make a comment he... greenie 19 years ago ...
... ribavirin therapy. Financial accessibility issues highlighted. Findings support switch to more effective and affordable direct- ... 2001) Peginterferon Alfa-2b plus Ribavirin Compared with Interferon Alfa-2b plus Ribavirin for Initial Treatment of Chronic ... In terms of safety, in our study, we experienced 5 out of 26 cases (19.2% of pegylated interferon + ribavirin patients) of ... The treatment of HCV with IFN + ribavirin in Benin is effective especially for genotype 2. But its adverse effects are manifold ...
Ribavirin was temporarily discontinued due to anemia in ten patients. Twenty-four patients required ribavirin dose reduction, ... Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis ... Key Words: Hepatitis C virus, Genotype, Peginterferon alfa-2b, Ribavirin, Treatment Core tip: In a multicenter study, the ... Ribavirin dose was reduced to half if hemoglobin level was , 10 g/dL; treatment was discontinued if hemoglobin level was , 8.5 ...
REBETOL (ribavirin) is known to be substantially excreted by the kidney, and the risk of adverse reactions to ribavirin may be ... Ribavirin demonstrated increased incidences of mutation and cell transformation in multiple genotoxicity assays. Ribavirin was ... Adequate studies to assess the carcinogenic potential of ribavirin in animals have not been conducted. However, ribavirin is a ... the maximum recommended human 24-hour dose of ribavirin). Treatment and Posttreatment: Potential Risk to the Fetus Ribavirin is ...
Core tip: Between 20% and 40% of hepatitis C virus patients treated with interferon-α and ribavirin develop autoantibodies ... Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy. World J Gastroenterol ... In cell culture, IMPDH2 inhibition by ribavirin promotes its aggregation into RR structures. These observations led to the ... Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy ...
To date, HEV infections can only be treated with ribavirin (RBV). Major drawbacks of this therapy are that RBV is not approved ... Figure 2. Mode of action of ribavirin. (A) Several antiviral mechanisms for ribavirin have been proposed and are depicted ... Figure 2. Mode of action of ribavirin. (A) Several antiviral mechanisms for ribavirin have been proposed and are depicted ... Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin ...
Home › Forums › Student Teams › order generic Ribavirin France, Ribavirin and harvoni treatment ...
... ribavirin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, ... ribavirin oral RIBAVIRIN SOLUTION - ORAL (RYE-ba-VYE-rin) COMMON BRAND NAME(S): Rebetol WARNING: Ribavirin may cause birth ... encoded search term (ribavirin (Rebetol%2C Ribasphere)) and ribavirin (Rebetol, Ribasphere) What to Read Next on Medscape ... ribavirin, and azathioprine for pancytopenia, and do not reintroduce pegylated interferon/ribavirin with concomitant ...
The blood samples were taken on day 9 of a 10-day therapeutic regimen of ribavirin and 1 month after the cessation of therapy. ... Conclusions: These results showed that ribavirin has a reversible genotoxic effect in humans and this effect could be due to ... In addition, on day 9, SCE and MN values were statistically different from the values of no-ribavirin control group. ... The main objective of this study was to assess the genotoxicity of ribavirin in 15 patients who were suffering from Crimean- ...
Plasma ribavirin is removed by hemodialysis with an extraction ratio of approximately 50%; however, due to the large volume of ... Ribavirin plasma exposures were approximately 20% lower in subjects with ESRD on HD compared to subjects with normal renal ... Ribavirin plasma exposures in these subjects were approximately 20% lower compared to subjects with normal renal function ... FDA Updates Dosing of Pegasys plus Ribavirin for Hepatitis C Patients with Kidney Impairment * ...
New Ribavirin in Early Development. Normal ALT in African-Americans. Fats, Overweight, Diabetes in HCV. How Often Should You Do ... In a poster today they reported that in monkeys they found Levovirin gets into the red blood cell less than ribavirin. This ... Levovirin is a second generation ribavirin being made by ICN Pharmacueticals. ...
... plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ...
nbsp; Key words: Crimean-Congo hemorrhagic fever virus, homology modeling, Ribavirin, RNA-dependent RNA polymerase. ... nbsp; Key words: Crimean-Congo hemorrhagic fever virus, homology modeling, Ribavirin, RNA-dependent RNA polymerase. ... into consideration to focus on the prediction of the specific ligand binding site by docking against antiviral drug Ribavirin, ... into consideration to focus on the prediction of the specific ligand binding site by docking against antiviral drug Ribavirin, ...
ribavirin. The patient must have been treated for at least 12 weeks.. - Washout period of at least 6 months from previous ... Ribavirin.. - Liver biopsy consistent with chronic hepatitis C within the last 12 months before. treatment starts, and at least ...
Ratio of ribavirin EC50 to compound EC50 for Respiratory syncytial virus infected cell system assessed as inhibition of viral ...
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of HCV genotype 1-infected patients. ... TITLE = {Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of HCV genotype 1-infected patients},. ...
ribavirin; hepatitis E virus; transplantation; immunosuppression; NK cells. Dewey Decimal Classification:. 600 Technology , 610 ... Immunomodulation of Natural Killer Cell Function by Ribavirin Involves TYK-2 Activation and Subsequent Increased IFN-γ ... and fulminant courses are observed especially in immunocompromised transplant recipients since administration of ribavirin (RBV ... and fulminant courses are observed especially in immunocompromised transplant recipients since administration of ribavirin (RBV ...
Be the first to review "Ribahep 200 mg (Ribavirin)" Cancel reply. Your email address will not be published. Required fields are ...
The Center and its activities are supported in part by a grant from the National Institute of General Medical Sciences (P30GM114737) of the National Institutes of Health. ...
... author of Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection ...
Be the first to review "RIBASAB (RIBAVIRIN)" Cancel reply. Your email address will not be published. Required fields are marked ...
  • Many HCV patients will take ribavirin for 24-48 weeks dependent on genotype. (curezone.com)
  • The treatment of HCV with IFN + ribavirin in Benin is effective for genotype 2. (scirp.org)
  • DAKLINZA is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection [see DOSAGE AND ADMINISTRATION and Clinical Studies ]. (rxlist.com)
  • Consider screening for the presence of NS5A polymorphisms at amino acid positions M28, Q30, L31, and Y93 in patients with cirrhosis who are infected with HCV genotype 1a prior to the initiation of treatment with DAKLINZA and sofosbuvir with or without ribavirin [see Microbiology , Table 11]. (rxlist.com)
  • The optimal duration of DAKLINZA and sofosbuvir with or without ribavirin has not been established for HCV genotype 3 patients with cirrhosis or for HCV genotype 1 patients with Child-Pugh C cirrhosis [see Clinical Studies ]. (rxlist.com)
  • NCT01573351) treated patients with chronic hepatitis C virus (HCV) genotype 1 (n=354) or 4 (n=44) infection who had a prior null or partial response to peginterferon/ribavirin. (pasteur.fr)
  • Daclatasvir plus asunaprevir and peginterferon/ribavirin demonstrated SVR12 rates of 93% (95% CI 90-96) in prior non-responders infected with HCV genotype 1. (pasteur.fr)
  • Daclatasvir plus asunaprevir and peginterferon/ribavirin demonstrated high rates of SVR12 in genotype 1- or 4-infected prior null or partial responders. (pasteur.fr)
  • I am a genotype 3 and was on trtmnt of interferon plus ribavirin for 4 months. (webmd.com)
  • We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. (johnshopkins.edu)
  • The backbone of treatment for chronic hepatitis C virus (HCV) infection regardless of genotype was combination therapy with injectable pegylated interferon-alfa (PEG-IFNa) plus oral ribavirin. (medscape.com)
  • The direct-acting antiviral agents (DAAs), first introduced in 2011, offered enhanced efficacy when combined with both PEG-IFN and ribavirin, particularly for genotype 1 infections. (medscape.com)
  • Depending on the genotype and other variables (eg, presence of cirrhosis, post liver transplantation), the regimen may also include ribavirin. (medscape.com)
  • Prediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C . (bvsalud.org)
  • To assess the effects of ribavirin for treating people with Crimean Congo haemorrhagic fever. (altmetric.com)
  • Statins may improve this combination's efficacy in treating hepatitis C. Ribavirin is the only known treatment for a variety of viral hemorrhagic fevers, including Lassa fever, Crimean-Congo hemorrhagic fever, Venezuelan hemorrhagic fever, and Hantavirus infection, although data regarding these infections are scarce and the drug might be effective only in early stages. (wikipedia.org)
  • Do not take ribavirin if you are pregnant or plan to become pregnant. (medlineplus.gov)
  • Do not take ribavirin if your partner is pregnant or plans to become pregnant. (medlineplus.gov)
  • Take ribavirin at around the same times every day. (medlineplus.gov)
  • Take ribavirin exactly as directed. (medlineplus.gov)
  • If you are a woman, do not take ribavirin if you are pregnant. (medications.su)
  • If you are a man, do not take ribavirin if your female sexual partner is pregnant. (medications.su)
  • Ribavirin targeted eIF4E in AML patients in monotherapy and combination studies and this corresponded to objective clinical responses including complete remissions. (wikipedia.org)
  • Monotherapy with pegylated interferon, ribavirin, or any direct-acting antiviral agent (eg, simeprevir, sofosbuvir) is not recommended, due to their lack of efficacy. (medscape.com)
  • Peginterferon plus ribavirin is the recommended treatment for chronic hepatitis C. However, ribavirin monotherapy may be considered for some patients. (regionh.dk)
  • Dyk ned i forskningsemnerne om 'Ribavirin monotherapy for chronic hepatitis C'. Sammen danner de et unikt fingeraftryk. (regionh.dk)
  • Ribavirin monotherapy for chronic hepatitis C . Cochrane Database of Systematic Reviews , (4), CD005527. (regionh.dk)
  • We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. (nih.gov)
  • In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone. (nih.gov)
  • Chronic and fulminant courses are observed especially in immunocompromised transplant recipients since administration of ribavirin (RBV) does not always lead to a sustained virologic response. (uni-regensburg.de)
  • Ribavirin is not effective when used alone to treat hepatitis C. It must be used together with an interferon alfa product (such as Peg-Intron or Intron A) to treat chronic hepatitis C. (medications.su)
  • Ribahep (Ribavirin) is used in combination with other antiviral medications to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. (heethealthcare.net)
  • It is indicated for the treatment of chronic hepatitis C genotypes 1 and 4 infection in combination with peginterferon alfa and ribavirin. (medscape.com)
  • Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. (bvsalud.org)
  • This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this patient population. (pasteur.fr)
  • Dive into the research topics of 'Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C'. Together they form a unique fingerprint. (johnshopkins.edu)
  • Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C . New England Journal of Medicine , 360 (3), 257-267. (johnshopkins.edu)
  • In this former indication the oral (capsule or tablet) form of ribavirin is used in combination with pegylated interferon alfa, including in people coinfected with hepatitis B, HIV and in the pediatric population. (wikipedia.org)
  • Ribavirin comes as a tablet, a capsule and an oral solution (liquid) to take by mouth. (medlineplus.gov)
  • The cost for ribavirin oral capsule 200 mg is around $71 for a supply of 42 capsules, depending on the pharmacy you visit. (drugs.com)
  • Pioneers in the industry, we offer ribahet ribavirin 200mg capsule, ribahep ribavirin 200mg capsules, ribamac ribavirin 200mg and ribamune ribavirin 200 mg from India. (heethealthcare.net)
  • Your doctor may decrease your dose or tell you to stop taking ribavirin if you develop side effects of the medication or if certain laboratory tests show that your condition has not improved. (medlineplus.gov)
  • A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks. (nih.gov)
  • Aim: The main objective of this study was to assess the genotoxicity of ribavirin in 15 patients who were suffering from Crimean-Congo haemorrhagic fever and treated with the therapy dose of the antiviral agent. (tubitak.gov.tr)
  • On August 9, 2011, the U.S. Food and Drug Administration (FDA) approved changes to the product label information for pegylated interferon alfa-2a (Pegasys) plus the Copegus brand of ribavirin, reflecting new dose recommendations for people with impaired kidney function. (hivandhepatitis.com)
  • Ribavirin plasma exposures were approximately 20% lower in subjects with ESRD on HD compared to subjects with normal renal function receiving the standard 1000/1200 mg Copegus daily dose. (hivandhepatitis.com)
  • Subjects with moderate (n=17) or severe (n=14) renal impairment did not tolerate 600 mg or 400 mg daily doses of Copegus, respectively, due to Copegus-related adverse reactions, mainly anemia, and exhibited 20 to 30% higher ribavirin plasma exposures (despite frequent dose modifications) compared to subjects with normal renal function (creatinine clearance greater than 80 mL/min) receiving the standard dose of Copegus. (hivandhepatitis.com)
  • Pharmacokinetic modeling and simulation indicates that a dose of 200 mg daily in patients with severe renal impairment and a dose of 200 mg daily alternating with 400 mg the following day in patients with moderate renal impairment will provide plasma ribavirin exposure similar to patients with normal renal function receiving the approved regimen of Copegus. (hivandhepatitis.com)
  • The ribavirin dose is based on weight. (medscape.com)
  • [ 8 ] whereas the initial clinical trials with peginterferon alfa-2b utilized ribavirin at a dose of 800-1400 mg per day. (medscape.com)
  • One patient did not tolerate interferon, but is in renal remission with low-dose ribavirin. (qxmd.com)
  • Average daily ribavirin dose was 200-800 mg. (qxmd.com)
  • Ribavirin-induced anaemia was managed in five of seven patients with low-dose iron and erythropoietin between 4000 and 20 000 IU/week. (qxmd.com)
  • METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. (johnshopkins.edu)
  • Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy. (wjgnet.com)
  • Ribavirin will not treat hepatitis C (a virus that infects the liver and may cause severe liver damage or liver cancer) unless it is taken with another medication. (medlineplus.gov)
  • It is not known if treatment that includes ribavirin and another medication cures hepatitis C infection, prevents liver damage that may be caused by hepatitis C, or prevents the spread of hepatitis C to other people. (medlineplus.gov)
  • It is a 3-carboxamidine prodrug of ribavirin, developed to target the liver and subsequently avoid the erythrocyte accumulation (with resulting anemia) often associated with ribavirin therapy. (news-medical.net)
  • Pharmacologic studies in rats have revealed that viramidine targets the liver more effectively than ribavirin, as adenosine deaminase conversion of viramidine to ribavirin occurs in the liver, trapping the drug within that organ. (news-medical.net)
  • Ribahep (Ribavirin) works by reducing the amount of hepatitis C virus in your body, which may help your liver recover. (heethealthcare.net)
  • Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C and some viral hemorrhagic fevers. (wikipedia.org)
  • Ribavirin is used primarily to treat hepatitis C and viral hemorrhagic fevers (which is an orphan indication in most countries). (wikipedia.org)
  • Although treatment for viral hepatitis C (VHC) has been around for many years and is widely used in developed countries, the high cost of pharmaceuticals (pegylated interferon and ribavirin) and pre-, per-, and post-treatment assessment has long been a brake on its implementation in developing countries, including Benin. (scirp.org)
  • Contrary to what the National Centre for Disease Control wants Nigerians to believe, Ribavirin, the only drug currently being used in the treatment of Lassa, fever does not suppress viral transmission, viral production, or enhance immune response. (punchng.com)
  • Ribavirin is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a) and other viral infections. (heethealthcare.net)
  • Ribahep (Ribavirin) triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral) and can be incorporated into RNA in RNA viral species. (heethealthcare.net)
  • Ribahep (Ribavirin) is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity. (heethealthcare.net)
  • In a viral haemorrhagic disease where up to 40% of people developing it die, it is remarkable that doctors still do not agree whether the only recognised treatment, an antiviral drug called ribavirin, makes a difference. (mybestmedicine.com)
  • My taking ribavirin was in relation to being treated for hepatitis C and my therapy was experimental and lasted 100 weeks. (curezone.com)
  • The objectives of this work were twofold: 1) to evaluate the effectiveness and safety of treatment with classic dual interferon pegylated alpha-2a (IFN) and ribavirin therapy in Benin, and 2) to present problems related to financial accessibility to this treatment. (scirp.org)
  • Two treatment regimens are available: traditional dual therapy (interferon + ribavirin) used since 2010 and direct-acting antivirals (DAAs) since the end of 2015. (scirp.org)
  • The blood samples were taken on day 9 of a 10-day therapeutic regimen of ribavirin and 1 month after the cessation of therapy. (tubitak.gov.tr)
  • Nonresponder to a previous course of therapy with either IFN alone or IFN plus ribavirin. (knowcancer.com)
  • Regimens containing pegylated interferon and ribavirin were the backbone of HCV therapy from 2001 until 2014. (medscape.com)
  • Ribavirin is in a class of antiviral medications called nucleoside analogues. (medlineplus.gov)
  • Ribavirin is a synthetic nucleoside with antiviral activity. (nih.gov)
  • Ribavirin is used with an interferon medication such as peginterferon alfa-2a [Pegasys] or peginterferon alpha-2b [PEG-Intron]) to treat hepatitis C in people who have not been treated with an interferon before. (medlineplus.gov)
  • The enzyme inosine triphosphate pyrophosphatase (ITPase) dephosphorylates ribavirin triphosphate in vitro to ribavirin monophosphate, and ITPase reduced enzymatic activity present in 30% of humans potentiates mutagenesis in hepatitis C virus. (wikipedia.org)
  • Ribahep ( Ribavirin) is readily phosphorylated intracellularly by adenosine kinase to Ribahep ( Ribavirin) mono-, di-, and triphosphate metabolites. (heethealthcare.net)
  • Another study found that ribavirin potentiated the antiviral effect of acyclovir. (wikipedia.org)
  • To minimize ribavirin-induced hemolysis and increase its antiviral effect, considerable efforts have been made involving chemical prodrugs and various formulations. (news-medical.net)
  • Conclusions: These results showed that ribavirin has a reversible genotoxic effect in humans and this effect could be due to toxic metabolites of ribavirin. (tubitak.gov.tr)
  • Use Ribahep (Ribavirin) as directed by your doctor. (heethealthcare.net)
  • Ribahep (Ribavirin) comes with an extra patient information sheet called a Medication Guide. (heethealthcare.net)
  • Read it again each time you get Ribahep (Ribavirin) refilled. (heethealthcare.net)
  • Take Ribahep (Ribavirin) by mouth with food. (heethealthcare.net)
  • Drinking extra fluids while you are taking Ribahep (Ribavirin) is recommended. (heethealthcare.net)
  • Take Ribahep (Ribavirin) on a regular schedule to get the most benefit from it. (heethealthcare.net)
  • Taking Ribahep (Ribavirin)at the same times each day will help you remember to take it. (heethealthcare.net)
  • Ask your health care provider any questions you may have about how to use Ribahep (Ribavirin). (heethealthcare.net)
  • Brand names for ribavirin include Virazole . (drugs.com)
  • Ribavirin is a prodrug, which when metabolized resembles purine RNA nucleotides. (wikipedia.org)
  • Reversal of the in vitro antiviral activity by guanosine or xanthosine suggests ribavirin may act as an analogue of these cellular metabolites. (nih.gov)
  • Patients received daclatasvir 60 mg once-daily plus asunaprevir 100mg twice-daily, with weekly peginterferon alfa-2a and weight-based ribavirin for 24 weeks. (pasteur.fr)
  • Assessment for administering ribavirin transmitted by consumption of contaminated water, treatment was made on a case-by-case basis according to undercooked infected pork or wild boar, deer, or rabbit clinical and therapeutic context. (cdc.gov)
  • Ribavirin has also been used as a treatment for herpes simplex virus. (wikipedia.org)
  • In addition to the above, ribavirin has been shown to have in vitro activity against influenza A and B viruses and herpes simplex virus, but the clinical significance of these data is unknown. (nih.gov)
  • Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with ribavirin and each time you refill your prescription. (medlineplus.gov)
  • Ribavirin resistance in AML patients arose leading to loss of eIF4E targeting and relapse. (wikipedia.org)
  • In HPV related oropharyngeal cancers, ribavirin reduced levels of phosphorylated form of eIF4E in some patients. (wikipedia.org)
  • 3 One study also showed that RSV-specific IgE antibody in bronchial secretions was decreased in patients treated with aerosolized Ribavirin for Inhalation Solution, USP. (nih.gov)
  • We included all patients treated with IFN + ribavirin for hepatitis C at CNHU/HKM. (scirp.org)
  • Between 20% and 40% of hepatitis C virus patients treated with interferon-α and ribavirin develop autoantibodies showing a peculiar antinuclear antibodies pattern characterized as rods and rings (RR) structures. (wjgnet.com)
  • Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. (qxmd.com)
  • Seven patients, two with cryoglobulinaemia, vasculitic manifestations and glomerulonephritis (GN), four with MPGN and one with FSGS were treated with a combination of interferon and ribavirin. (qxmd.com)
  • Two patients were given pegylated interferon and ribavirin. (qxmd.com)
  • On the other hand, if ribavirin does work, then it needs to be rolled out to all patients who could benefit, which is currently not the case. (mybestmedicine.com)
  • It is noted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) that "Ribavirin has poor in vitro and in vivo activity against the filoviruses (Ebola and Marburg) and the flaviviruses (dengue, yellow fever, Omsk hemorrhagic fever, and Kyasanur forest disease)" The aerosol form has been used in the past to treat respiratory syncytial virus-related diseases in children, although the evidence to support this is rather weak. (wikipedia.org)
  • The pyrazole-3-carboxamide derivatives (which are formally considered as 4-deaza-analogues of ribavirin) have shown activity against T-cell lymphocytes and influenza viruses in vitro . (news-medical.net)
  • Ribavirin has demonstrated antiviral activity against RSV in vitro 1 and in experimentally infected cotton rats. (nih.gov)
  • Ribavirin only efficiently suppresses the replication of Lassa virus in vitro (in a test tube), and shows only moderate efficacy in reducing presence of viruses in the blood in a living organism. (punchng.com)
  • The focus is state-level budget practices and their impact on institutions.We aimed to investigate the impact of IFN- and ribavirin (RBV)-free therapies on HRQoL and fatigue.Consideration of the context of the health care system is of paramount importance. (xtelesis.in)
  • Improved therapies for peginterferon/ribavirin null or partial responders are needed. (pasteur.fr)
  • In cell cultures the inhibitory activity of ribavirin for respiratory syncytial virus (RSV) is selective. (nih.gov)
  • Ribavirin is a member of the inhaled anti-infectives drug class and is commonly used for Hepatitis C, and Respiratory Syncytial Virus. (drugs.com)
  • cerning efficacy and safety of ribavirin are scarce ( 12 ). (cdc.gov)
  • [ 7 ] Ribavirin continues to play a key role in a wide variety of HCV treatment regimens. (medscape.com)
  • Ribavirin for inhalation solution, USP is a sterile, lyophilized powder to be reconstituted for aerosol administration. (nih.gov)
  • Each 100 mL glass vial contains 6 grams of ribavirin, and when reconstituted to the recommended volume of 300 mL with Sterile Water for Injection, USP or Sterile Water for Inhalation (no preservatives added), will contain 20 mg of ribavirin per mL, pH approximately 5.5. (nih.gov)
  • Neutralizing antibody responses to RSV were decreased in aerosolized Ribavirin for Inhalation Solution, USP-treated infants compared to placebo-treated infants. (nih.gov)
  • Assay for Ribavirin for Inhalation Solution, USP in human materials is by a radioimmunoassay which detects ribavirin and at least one metabolite. (nih.gov)
  • The author concludes that exhausted plastic enclosures maintained under negative pressure may be able to control the spread of ribavirin aerosol to adjacent areas. (cdc.gov)
  • Derivatives of ribavirin are also prepared by enzymatic synthesis and Vorbrüggen coupling methods. (news-medical.net)
  • In rats, ribavirin administration resulted in lymphoid atrophy of the thymus, spleen and lymph nodes. (nih.gov)
  • For adverse effects (including haemolytic anaemia and a need to discontinue treatment), we do not know whether there is an increased risk with ribavirin in people with CCHF as data are insufficient.We do not know if adding ribavirin to early supportive care improves outcomes. (altmetric.com)
  • The mechanism of action of ribavirin is not entirely clear. (wikipedia.org)
  • S a problem with impulsivity, we would have expected to see decreased responses to those sexual Ribavirin Buy Usa images. (xtelesis.in)
  • Drink extra fluids while you are taking ribavirin to keep from getting dehydrated, especially during exercise or in hot weather. (medications.su)